Back to search

University of British Columbia

Establishing in vitro models of vaginal infections

Abstract

dc:description

Sexually transmitted infections cause a large global health burden and disproportionately impact women. Herpes simplex virus-2 (HSV-2) and Zika virus (ZIKV) are sexually transmitted viruses that cause vaginal pathogenesis in women and can also harm fetal and neonatal health. There are currently no vaccines available against these viruses. There are no approved antivirals against ZIKV, and antivirals against HSV-2 cannot treat infection or prevent viral shedding, intensifying the need for novel therapeutics. There is also a lack of physiologically accurate in vitro models of vaginal infections that would improve our understanding of vaginal pathogenesis and contribute to the development of novel antiviral strategies. We have previously identified endogenous retrovirus (ERV)-mediated protection as a potential antiviral strategy against HSV-2. ERVs are “fossilized” remnants of germline infection and integration by ancient retroviruses that are implicated in human and health and disease, including protection against exogenous viruses. However, the mechanism of previously observed ERV-mediated protection against HSV-2 remains to be elucidated. My thesis aimed to address these gaps by accomplishing two main objectives: first, establishing a mouse vaginal organoid model of HSV-2 and ZIKV infection and second, using vaginal organoids and tail keratinocytes to investigate mechanisms of ERV-mediated protection against HSV-2. I hypothesized that vaginal organoids would support HSV-2 and ZIKV replication, and that both organoids and keratinocytes would show ERV-dependent restriction of HSV-2 in a cell-intrinsic manner. I found that vaginal organoids expressed markers of basal and apical differentiation, supported HSV-2 and ZIKV replication, and were capable of expressing interferon stimulated genes in response to interferon treatment. I also found that organoids and keratinocytes derived from mice with systemically elevated levels of ERVs could not restrict HSV-2 replication, thus ruling out cell-intrinsic resistance as a mechanism of ERV-mediated antiviral protection. Altogether, I was able to establish a novel, physiologically relevant, in vitro model of vaginal HSV-2 and ZIKV infection. This model of vaginal infection can be used in the future to model other vaginal pathogens, investigate mechanisms of vaginal pathogenesis, and develop novel therapeutic strategies against sexually transmitted infections.

Degree

thesis:*
Name thesis:degree_name
Master of Science - MSc
Level thesis:degree_level
master's
Discipline thesis:degree_discipline
Microbiology and Immunology
Grantor dc:publisher
University of British Columbia
Year dc:date
2024

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Saraph, Ananya
Contributors dc:contributor
  • Tokuyama, Maria

Rights

dc:rights
Statement dc:rights
  • Attribution-NonCommercial-NoDerivatives 4.0 International
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/89457

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Saraph, Ananya. Establishing in vitro models of vaginal infections. master's thesis, University of British Columbia, 2024. http://hdl.handle.net/2429/89457